Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
12:00pm, Saturday, 30'th May 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
02:30am, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
02:05am, Wednesday, 13'th May 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes throu
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
04:05pm, Thursday, 30'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-c
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 24'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving p
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Consensus Rating of “Moderate Buy” from Analysts
04:09am, Monday, 20'th Apr 2026
Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratin
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates
11:07am, Thursday, 16'th Apr 2026
The agreement aims to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection in Greater China, which is expected to enhance its market position significantly.
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 05'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thr
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
08:00am, Thursday, 26'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-cl
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
08:00am, Monday, 23'rd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 30'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
08:00am, Wednesday, 21'st Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
